Growth Hormone Secretagogue
Dragon Pharma Peptide Product
Dragon Pharma Hexarelin is supplied as a lyophilized powder in a 2 mL vial and contains the growth hormone-releasing peptide examorelin at a labeled strength of 5 mg. Product specifications, a batch-specific lab report, storage information, and available payment options are provided below.
Each vial contains a labeled strength of 5 mg of examorelin (Hexarelin).
Supplied as a freeze-dried powder that requires reconstitution with bacteriostatic water before use.
Packaged in a standard 2 mL peptide vial with a rubber stopper and aluminum seal.
A published lab report from September 2025 provides measured results for the identified batch.
| Product name | Hexarelin 5 mg |
|---|---|
| Active substance | Examorelin (Hexarelin) |
| Labeled strength | 5 mg/vial |
| Container | 2 mL vial |
| Total labeled content | 5 mg per vial |
| Product form | Lyophilized powder |
| Manufacturer | Dragon Pharma |
The latest published report for batch #HEXAHD6, dated September 12, 2025, measured 5.34 mg against the stated 5 mg labeled strength.
Open the Lab Reports tab to view the full report and check the batch number associated with the test.
Other peptide options from the same product line include GHRP-2 5 mg, GHRP-6 10 mg, and Ipamorelin 5 mg, all of which are growth hormone-releasing peptides with different properties. Hexarelin is known for its potent growth hormone-releasing activity in research settings.
Published Test Result
A published lab report for Dragon Pharma Hexarelin 5 mg is provided below with the test date, measured result and reported batch number. The result can be compared directly with the product's labeled strength of 5 mg.
Science & Research
Hexarelin, also known as examorelin, is a synthetic growth hormone-releasing peptide that acts on the ghrelin receptor to stimulate growth hormone release. This section provides a brief overview of what is known about this peptide from research literature.
Hexarelin belongs to the class of growth hormone-releasing peptides (GHRPs) that act on the ghrelin receptor to stimulate growth hormone secretion from the pituitary gland.
Hexarelin binds to the ghrelin (growth hormone secretagogue) receptor, which is distinct from the GHRH receptor. This binding triggers a signaling cascade that leads to growth hormone release.
Preclinical research has investigated Hexarelin for its potential effects on growth hormone release and related physiological processes. It is one of the more potent GHRPs studied in research settings.
This product is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water or sterile water for injection before use. The addition of water converts the freeze-dried powder into a solution suitable for research applications.
The reconstituted peptide solution should be stored as recommended on the product label. Peptide solutions are typically refrigerated and used within a specified timeframe after reconstitution to maintain integrity.
Peer-reviewed research on Hexarelin is available through the National Institutes of Health and other scientific databases. The following link provides general information on this peptide and its mechanism of action.
Important Health Information
Peptide research compounds such as Hexarelin have limited clinical safety data. The information below is derived from published preclinical research and general knowledge of the growth hormone axis and does not constitute medical advice.
Hexarelin has not been extensively studied in humans. The available safety information comes primarily from preclinical research.
Peptides that stimulate growth hormone release have the potential to affect glucose metabolism, insulin sensitivity and fluid balance. These effects are not well characterized for Hexarelin.
Subcutaneous injection carries risks including injection-site reactions, infection and improper technique. Sterile handling and correct reconstitution procedures are essential.
Compounds that affect the growth hormone axis may interact with other hormonal systems, including thyroid and adrenal function. The potential significance of these interactions is not fully understood.
Growth hormone-releasing peptides may have central nervous system effects in preclinical research, including effects on sleep and appetite. The clinical significance of these findings is unknown.
This peptide research compound should not be used by individuals with known allergies or sensitivities to peptide compounds, or by those who are pregnant, nursing or have active malignancies.
Medical advice is particularly important for individuals with diabetes or glucose metabolism disorders, cardiovascular disease, cancer or a history of cancer, pituitary disorders, or those taking medications that affect hormone levels. This peptide should not be used during pregnancy or breastfeeding.
The product should also be stored securely to prevent accidental access or use by children or other household members, particularly after reconstitution when it contains a liquid solution.
Growth hormone-releasing peptides, including Hexarelin, are prohibited under anti-doping rules in tested sport at all times unless an applicable therapeutic-use exemption has been granted.
The current status and applicable rules can be checked through the World Anti-Doping Agency Prohibited List.
Common Product Questions
Quick answers about Hexarelin 5 mg specifications, the published lab report, storage, shipping, Bitcoin payment and general product information.
Dragon Pharma Hexarelin 5 mg is a lyophilized peptide product containing 5 mg of examorelin (Hexarelin) per vial. It is supplied in a 2 mL vial for research purposes.
Hexarelin and examorelin are the same compound. Examorelin is the international nonproprietary name (INN) for the peptide commonly referred to as Hexarelin.
Each vial contains a labeled strength of 5 mg of Hexarelin.
The product is supplied as a lyophilized powder in a 2 mL vial. It requires reconstitution with bacteriostatic water or sterile water for injection before use.
The published lab report dated September 12, 2025 for batch #HEXAHD6 measured 5.34 mg against the stated 5 mg labeled strength.
No. Each report applies to the sample submitted for that specific test and the batch identified in the report. It does not independently verify the content or condition of every individual vial.
Store the lyophilized powder in its original packaging at room temperature or refrigerated, protected from excessive heat, moisture and direct light. Once reconstituted, peptide solutions typically require refrigeration and should be used within a limited timeframe. Always follow the specific storage directions printed on the product label.
Lyophilized peptide powders are generally stable at room temperature but should be protected from heat. After reconstitution, peptide solutions typically require refrigeration. Check the product label for specific storage instructions.
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4–5 business days after dispatch, while shipments from the International Warehouse typically take 15–20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy Hexarelin 5 mg with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Growth hormone-releasing peptides, including Hexarelin, are prohibited under anti-doping rules in tested sport unless an applicable therapeutic-use exemption has been granted. Current requirements should be checked against the relevant anti-doping rules before competition.
Additional research on this peptide is available through the National Institutes of Health and other scientific databases. A direct link to PubMed references is provided in the Science & Research section above.